Biotech Values

[DewDiligence]

COLY – Glad to hear you got out before now. If COLY had had the HCV arena to themselves, I’d have considered the initial Actilon data encouraging. But amid the other HCV programs in development from an array of companies, Actilon just didn’t compute from a business standpoint, IMO. It was one of the very few phase-2 HCV programs without a big-name partner, and there was a reason for that. Regards, Dew